46 Results
Conversations at the Opening of IAS 2023
The International AIDS Society’s 12th Conference on HIV Science (IAS 2023) opened Sunday, with thousands of scientists, policy leaders, and advocates gathered to present and discuss the latest advances in HIV research. HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
IAS Conference Highlights—Heart Disease Prevention for People with HIV, Long-acting HIV Prevention and Treatment
During the first full day of sessions at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov shared conversations on important study findings about reducing cardiovascular disease among people with HIV and the latest developments with long-acting prevention and treatment options that could one day become safe and effective alternatives to daily oral pills.
Study Finds That People Who Recover From Ebola Virus Infection Can Have Healthy Pregnancies and Children
The Ebola outbreaks in 2014 and 2016 resulted in high mortality; however, many people who were infected recovered. Studies have demonstrated that after recovery Ebola virus can persist throughout the body in the eyes, brain, semen, human milk, and vaginal secretions.
Study Links Gut Microbiome Dysbiosis with Recurrent Urinary Tract Infections
Recurrent urinary tract infections (rUTI) affect people all around the world and contribute greatly to morbidity, especially for females. In the United States, over one million women seek medical care for rUTIs each year, which are most commonly caused by uropathogenic Escherichia coli (E. coli) and treated with antibiotics. While history of a prior UTI is a significant risk factor, other drivers...
A Secret to Health and Long Life? Immune Resilience, NIAID Grantees Report
Do you know some people who almost never get sick and bounce back quickly when they do, while other people frequently suffer from one illness or another? NIAID-supported researchers have pinpointed an attribute of the immune system called immune resilience that helps explain why some people live longer and healthier lives than others.
Promising Advances for Antibody Treatment of Viruses that Cause Neurologic and Arthritic Diseases
NIAID scientists and colleagues are one step closer to developing a safe and effective therapy against alphaviruses, which are spread by mosquitoes and can cause two types of disease in people: causing severe neurological impairment such as encephalitis (brain swelling) or crippling muscle pain similar to arthritis.
NIAID Study Describes Immune Response to Mpox in Woman Living with HIV
Mpox has been present in west, central and east Africa for decades, with the first human case identified in 1970. In May 2022, a global mpox outbreak caused by a specific strain of the virus (referred to as “clade IIb”) was the first epidemiologic evidence of community mpox transmission outside of the historically affected African regions. More than 80,000 cases and 140 mpox-related deaths have...
Register Now! Live with Leadership—A Conversation Commemorating National HIV Vaccine Awareness Day
Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The HIV.gov-hosted Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.
This engaging...
Universal Influenza Candidate Vaccine Performs Well in Phase 1 Trial
Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.
NIAID-Supported Study Provides Stronger Evidence of Link Between RSV and Childhood Asthma
The study found that infants who were not infected with RSV in the first year of life had a 26% lower risk of asthma at 5 years of age than those who were infected with RSV as infants.
Close-up view of protein-complex structures could lead to better flu vaccines
A new understanding of vaccine components gained through electron microscopy and other direct visualization techniques could help scientists design more effective seasonal influenza vaccines.
Multisite Study Identifies Factors Associated with HIV Incidence Among Transgender Women
Despite the high HIV burden among transgender women, access to health care among this demographic is low due to structural barriers that limit access to HIV prevention, testing, care, and other health services. Therefore, transgender women have been identified as a priority population in the Ending the HIV Epidemic in the U.S. (EHE) plan and National HIV/AIDS Strategy.
Some Reported Allergic Reactions to mRNA COVID-19 Vaccines Were Likely Stress Responses
Some responses to the mRNA COVID-19 vaccines reported as severe allergic reactions were likely a recently described, non-allergic condition called immunization stress-related response (ISRR), according to a study by investigators. The symptoms of ISRR can closely mimic those of a severe allergic reaction known as anaphylaxis, a potentially life-threatening, systemic allergic reaction in which the immune system releases a dangerous flood of chemicals.
CROI 2023—Dr. Dieffenbach Shares Research Highlights on Long-Acting HIV Prevention and Treatment, COVID, and a Cure Update
Dr. Dieffenbach, Director of the Division of AIDS, shared updates about some research on long-acting HIV prevention and treatment and COVID treatment and prevention. He also discussed news of another reported case of HIV cure.
HIV Vaccine Research Update with Dr. Dieffenbach from CROI 2023
The ongoing search for an HIV vaccine was among the topics discussed during the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Disease, about some key takeaways from those presentations. Watch our conversation with Dr. Dieffenbach below:
Mosaico...
Doxy-PEP for STIs and More—Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023
During the first full day of research presentations at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), about some initial highlights, including the opening session that featured a lecture by Dr. Anthony Fauci and several studies...
NIAID Researchers Identify Link Between Common Chemicals and Eczema
NIAID scientists have found an association between widely used chemicals called diisocyanates and atopic dermatitis, a chronic inflammatory skin disease commonly known as eczema.
Novel Study Model Reveals New Understanding of Fatal Familial Insomnia
Fatal familial insomnia (FFI) is a little-known yet horrific disease in which people die from lack of sleep. In a new study, NIAID scientists developed a cerebral organoid model to study the exact protein mutation that causes FFI.
NIAID-led Work Identifies Bacteria Signaling for Nerve Repair in Mice
A team of NIAID-led researchers has identified a mechanism in mice in which the immune system and commensal bacteria help repair damaged sensory neurons within the skin. They hope their findings could lead to therapies that stimulate recovery in people following skin injury and limit damage from chemotherapy and chronic diseases.
NIAID-Supported Studies Identify Universal Predictors of Antibody Response to Vaccination
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
Newly Discovered Species of Gut Bacteria May Cause Some Cases of Rheumatoid Arthritis
Research by NIAID grantees strongly suggests that immune responses to a newly discovered species of gut bacteria may cause some cases of a common autoimmune disease called rheumatoid arthritis. The findings were recently published in Science Translational Medicine.
